{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:46:48Z","timestamp":1791920808915,"version":"4.3.4"},"reference-count":307,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Leukemia is a heterogeneous group of hematologic malignancies characterized by distinct genetic and molecular abnormalities. Advancements in genomic technologies have significantly transformed the diagnosis, prognosis, and treatment strategies for leukemia. Among these, next-generation sequencing (NGS) has emerged as a powerful tool, enabling high-resolution genomic profiling that surpasses conventional diagnostic approaches. By providing comprehensive insights into genetic mutations, clonal evolution, and resistance mechanisms, NGS has revolutionized precision medicine in leukemia management. Despite its transformative potential, the clinical integration of NGS presents challenges, including data interpretation complexities, standardization issues, and cost considerations. However, continuous advancements in sequencing platforms and bioinformatics pipelines are enhancing the reliability and accessibility of NGS in routine clinical practice. The expanding role of NGS in leukemia is paving the way for improved risk stratification, targeted therapies, and real-time disease monitoring, ultimately leading to better patient outcomes. This review highlights the impact of NGS on leukemia research and clinical applications, discussing its advantages over traditional diagnostic techniques, key sequencing approaches, and emerging challenges. As precision oncology continues to evolve, NGS is expected to play an increasingly central role in the diagnosis and management of leukemia, driving innovations in personalized medicine and therapeutic interventions.<\/jats:p>","DOI":"10.3390\/hematolrep17020018","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T13:36:49Z","timestamp":1743169009000},"page":"18","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Genetic Profiling of Acute and Chronic Leukemia via Next-Generation Sequencing: Current Insights and Future Perspectives"],"prefix":"10.3390","volume":"17","author":[{"given":"Laras","family":"Pratiwi","sequence":"first","affiliation":[{"name":"Internal Medicine Study Program, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya 60132, Indonesia"},{"name":"Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawzia Hanum","family":"Mashudi","sequence":"additional","affiliation":[{"name":"Internal Medicine Study Program, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya 60132, Indonesia"},{"name":"Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukti Citra","family":"Ningtyas","sequence":"additional","affiliation":[{"name":"Internal Medicine Study Program, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya 60132, Indonesia"},{"name":"Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5730-2013","authenticated-orcid":false,"given":"Henry","family":"Sutanto","sequence":"additional","affiliation":[{"name":"Internal Medicine Study Program, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya 60132, Indonesia"},{"name":"Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradana Zaky","family":"Romadhon","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya 60132, Indonesia"},{"name":"Department of Internal Medicine, Airlangga University Hospital, Surabaya 60115, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"ref_1","unstructured":"Chennamadhavuni, A., Lyengar, V., Mukkamalla, S.K.R., and Shimanovsky, A. (2025). Leukemia. StatPearls, StatPearls Publishing."},{"key":"ref_2","unstructured":"Vakiti, A., Reynolds, S.B., and Mewawalla, P. (2025). Acute Myeloid Leukemia. StatPearls, StatPearls Publishing."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s43042-024-00563-w","article-title":"Prognosis and Treatment in Acute Myeloid Leukemia: A Comprehensive Review","volume":"25","author":"Debnath","year":"2024","journal-title":"Egypt. J. Med. Hum. Genet."},{"key":"ref_4","unstructured":"Puckett, Y., and Chan, O. (2025). Acute Lymphocytic Leukemia. StatPearls, StatPearls Publishing."},{"key":"ref_5","unstructured":"Mukkamalla, S.K.R., Taneja, A., Malipeddi, D., and Master, S.R. (2025). Chronic Lymphocytic Leukemia. StatPearls, StatPearls Publishing."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5306\/wjco.v12.i2.69","article-title":"Chronic Myeloid Leukemia-from the Philadelphia Chromosome to Specific Target Drugs: A Literature Review","volume":"12","author":"Sampaio","year":"2021","journal-title":"World J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1182\/blood.2024026311","article-title":"Long-Term Outcomes of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia","volume":"145","author":"Guilhot","year":"2025","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1038\/s41467-022-32103-8","article-title":"Unified Classification and Risk-Stratification in Acute Myeloid Leukemia","volume":"13","author":"Tazi","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Wemyss, C., Jones, E., Stentz, R., and Carding, S.R. (2024). Acute Myeloid Leukaemia and Acute Lymphoblastic Leukaemia Classification and Metabolic Characteristics for Informing and Advancing Treatment. Cancers, 16.","DOI":"10.3390\/cancers16244136"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1002\/1878-0261.12899","article-title":"Insights into the Molecular Profiles of Adult and Paediatric Acute Myeloid Leukaemia","volume":"15","author":"Aung","year":"2021","journal-title":"Mol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13073-019-0703-1","article-title":"Molecular Profiling for Precision Cancer Therapies","volume":"12","author":"Malone","year":"2020","journal-title":"Genome Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 Mutations in Acute Myeloid Leukemia: Therapeutic Paradigm beyond Inhibitor Development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/asheducation-2016.1.348","article-title":"Mutations in AML: Prognostic and Therapeutic Implications","volume":"2016","author":"DiNardo","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/modpathol.2008.13","article-title":"Targeted Therapy in Leukemia","volume":"21","author":"Downing","year":"2008","journal-title":"Mod. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/PPO.0b013e31823dec8d","article-title":"Evolution of Therapies for Chronic Myelogenous Leukemia","volume":"17","author":"Santos","year":"2011","journal-title":"Cancer J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"106942","DOI":"10.1016\/j.leukres.2022.106942","article-title":"Efficacy of FLT3 and IDH1\/2 Inhibitors in Patients with Acute Myeloid Leukemia Previously Treated with Venetoclax","volume":"122","author":"Bewersdorf","year":"2022","journal-title":"Leuk. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/17474086.2020.1818559","article-title":"Precision Medicine in Acute Myeloid Leukemia: Where Are We Now and What Does the Future Hold?","volume":"13","author":"Montesinos","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Li, W. (2022). Measurable Residual Disease Testing in Acute Leukemia: Technology and Clinical Significance. Leukemia, Exon Publications.","DOI":"10.36255\/exon-publications-leukemia-measurable-residual-disease"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Della Starza, I., De Novi, L.A., Elia, L., Bellomarino, V., Beldinanzi, M., Soscia, R., Cardinali, D., Chiaretti, S., Guarini, A., and Fo\u00e0, R. (2023). Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia. Cancers, 15.","DOI":"10.3390\/cancers15020374"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ajh.25484","article-title":"Optimizing Survival Outcomes with Post-remission Therapy in Acute Myeloid Leukemia","volume":"94","author":"Medeiros","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Sahoo, O.S., Aidasani, H., Nayek, A., Tripathi, S., Talukdar, J., Gul, A., Kumar, D., Dhar, R., and Karmakar, S. (2024). Role of Next-Generation Sequencing in Revolutionizing Healthcare for Cancer Management. MedComm\u2014Future Med., 3.","DOI":"10.1002\/mef2.70001"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Sagniez, M., Simpson, S.M., Caron, M., Rozendaal, M., Par\u00e9, B., Sontag, T., Langlois, S., Rouette, A., Lavall\u00e9e, V.-P., and Cellot, S. (2022). Real-Time Molecular Classification of Leukemias. medRxiv.","DOI":"10.1101\/2022.06.22.22276550"},{"key":"ref_25","unstructured":"Rindy, L.J., and Chambers, A.R. (2025). Bone Marrow Aspiration and Biopsy. StatPearls, StatPearls Publishing."},{"key":"ref_26","unstructured":"Jain, S., and Sharma, R. (2025). Laboratory Evaluation of Bone Marrow. StatPearls, StatPearls Publishing."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.blre.2017.01.003","article-title":"Bone Marrow Evaluation for Diagnosis and Monitoring of Acute Myeloid Leukemia","volume":"31","author":"Percival","year":"2017","journal-title":"Blood Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ajh.2830350405","article-title":"Dry Tap Bone Marrow Aspiration: Clinical Significance","volume":"35","author":"Humphries","year":"1990","journal-title":"Am. J. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"E600","DOI":"10.1002\/ajh.24839","article-title":"Limitations of Poor Bone Marrow Aspirations (for an Accurate Diagnosis) despite the Multimodal Analytical Era: A Longitudinal Retrospective Study","volume":"92","author":"Astle","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12308-021-00450-y","article-title":"Dry Tap on Bone Marrow Aspiration: A Red Flag","volume":"14","author":"Donald","year":"2021","journal-title":"J. Hematop."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.36106\/gjra\/5902136","article-title":"Comparative Evaluation of Simultaneous Bone Marrow Aspiration and Bone Marrow Biopsy in Diagnosis of Leukemic Patients\u2014An Institutional Study","volume":"12","author":"Azharuddin","year":"2023","journal-title":"Glob. J. Res. Anal."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.14740\/jh606","article-title":"Spontaneous Remission in a Patient With Acute Myeloid Leukemia Leading to Undetectable Minimal Residual Disease","volume":"9","author":"Helbig","year":"2020","journal-title":"J. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101209","DOI":"10.1016\/j.blre.2024.101209","article-title":"Cancer Cytogenetics in a Genomics World: Wedding the Old with the New","volume":"66","author":"Balciuniene","year":"2024","journal-title":"Blood Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1055\/s-0043-1768052","article-title":"Role of Cytogenetics and Fluorescence In Situ Hybridization in the Laboratory Workup of Acute Myeloid Leukemias","volume":"44","author":"Jain","year":"2023","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"ref_35","unstructured":"Ozkan, E., and Lacerda, M.P. (2025). Genetics, Cytogenetic Testing And Conventional Karyotype. StatPearls, StatPearls Publishing."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40880-016-0108-0","article-title":"The Philadelphia Chromosome in Leukemogenesis","volume":"35","author":"Kang","year":"2016","journal-title":"Chin. J. Cancer"},{"key":"ref_37","first-page":"535","article-title":"Cytogenetics in the Management of Acute Myeloid Leukemia: An Update by the Groupe Francophone de Cytog\u00e9n\u00e9tique H\u00e9matologique (GFCH)","volume":"74","author":"Luquet","year":"2016","journal-title":"Ann. Biol. Clin."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.seminoncol.2008.04.007","article-title":"Acute Myeloid Leukemia with a Complex Karyotype","volume":"35","year":"2008","journal-title":"Semin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/leu.2013.236","article-title":"Integration of Cytogenetic and Molecular Alterations in Risk Stratification of 318 Patients with de Novo Non-M3 Acute Myeloid Leukemia","volume":"28","author":"Hou","year":"2014","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Boscaro, E., Urbino, I., Catania, F.M., Arrigo, G., Secreto, C., Olivi, M., D\u2019Ardia, S., Frairia, C., Giai, V., and Freilone, R. (2023). Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors. Cancers, 15.","DOI":"10.3390\/cancers15133512"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"35445","DOI":"10.18632\/oncotarget.16367","article-title":"Pathogenesis of ETV6\/RUNX1-Positive Childhood Acute Lymphoblastic Leukemia and Mechanisms Underlying Its Relapse","volume":"8","author":"Sun","year":"2017","journal-title":"Oncotarget"},{"key":"ref_42","first-page":"547","article-title":"Cytogenetics in the Management of Children and Adult Acute Lymphoblastic Leukemia (ALL): An Update by the Groupe Francophone de Cytog\u00e9n\u00e9tique H\u00e9matologique (GFCH)","volume":"74","author":"Baranger","year":"2016","journal-title":"Ann. Biol. Clin."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00776-007-1215-1","article-title":"Advantages and Limitations of Cytogenetic, Molecular Cytogenetic, and Molecular Diagnostic Testing in Mesenchymal Neoplasms","volume":"13","author":"Bridge","year":"2008","journal-title":"J. Orthop. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1309\/AJCPP6LVMQG4LNCK","article-title":"Conventional Karyotyping and Fluorescence In Situ Hybridization","volume":"143","author":"He","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_45","first-page":"e1325","article-title":"Application of Fluorescence In Situ Hybridization (FISH) Technique for the Detection of Genetic Aberration in Medical Science","volume":"9","author":"Ratan","year":"2017","journal-title":"Cureus"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2353\/jmoldx.2007.060128","article-title":"Guidance for Fluorescence in Situ Hybridization Testing in Hematologic Disorders","volume":"9","author":"Wolff","year":"2007","journal-title":"J. Mol. Diagn."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexmp.2006.03.004","article-title":"Conventional Cytogenetics and FISH in the Detection of BCR\/ABL Fusion in Chronic Myeloid Leukemia (CML)","volume":"81","author":"Mark","year":"2006","journal-title":"Exp. Mol. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4274\/Tjh.2012.0180","article-title":"Co-Expression of t(15;17) and t(8;21) in a Case of Acute Promyelocytic Leukemia: Review of the Literature","volume":"30","author":"UZ","year":"2013","journal-title":"Turk. J. Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Abdool, A., Donahue, A.C., Wohlgemuth, J.G., and Yeh, C.-H. (2010). Detection, Analysis and Clinical Validation of Chromosomal Aberrations by Multiplex Ligation-Dependent Probe Amplification in Chronic Leukemia. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0015407"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/cyto.b.20390","article-title":"Impact of Trisomy 12, Del(13q), Del(17p), and Del(11q) on the Immunophenotype, DNA Ploidy Status, and Proliferative Rate of Leukemic B-Cells in Chronic Lymphocytic Leukemia","volume":"74B","author":"Quijano","year":"2008","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/978-1-4939-8876-1_4","article-title":"Analysis of Common Abnormalities Seen in Chronic Lymphocytic Leukemia Using Fluorescence In Situ Hybridization","volume":"Volume 1881","author":"Malek","year":"2019","journal-title":"Chronic Lymphocytic Leukemia"},{"key":"ref_52","first-page":"1038","article-title":"Detection of Gene Abnormalities in 43 Cases of Chronic Lymphocytic Leukemia by Fluorescence in Situ Hybridization","volume":"26","author":"Jing","year":"2018","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/14737159.2016.1227243","article-title":"Molecular Monitoring of Chronic Myeloid Leukemia: Present and Future","volume":"16","author":"Yeung","year":"2016","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_54","first-page":"26","article-title":"Comparative Analysis of Fluorescence In Situ Hybridization and Real Time Polymerase Chain Reaction in Diagnosis of Chronic Myeloid Leukemia","volume":"27","author":"Ali","year":"2017","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Bhat, T.A., and Wani, A.A. (2017). Fluorescence In Situ Hybridization (FISH) and Its Applications. Chromosome Structure and Aberrations, Springer.","DOI":"10.1007\/978-81-322-3673-3"},{"key":"ref_56","first-page":"4","article-title":"Molecular Testing for Acute Myeloid Leukemia","volume":"19","author":"Qin","year":"2022","journal-title":"Cancer Biol. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2017-02-734541","article-title":"Diagnosis and Classification of Hematologic Malignancies on the Basis of Genetics","volume":"130","author":"Taylor","year":"2017","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"100023","DOI":"10.1016\/j.amolm.2023.100023","article-title":"Biomarkers in Acute Myeloid Leukemia: From State of the Art in Risk Classification to Future Challenges of RNA Editing as Disease Predictor and Therapy Target","volume":"2","author":"Quattrocchi","year":"2023","journal-title":"Asp. Mol. Med."},{"key":"ref_59","unstructured":"Khehra, N., Padda, I.S., and Swift, C.J. (2025). Polymerase Chain Reaction (PCR). StatPearls, StatPearls Publishing."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/978-3-031-62731-6_14","article-title":"Function of PML-RARA in Acute Promyelocytic Leukemia","volume":"1459","author":"Testa","year":"2024","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cca.2015.12.001","article-title":"Rapid Diagnosis of Acute Promyelocytic Leukemia with the PML-RARA Fusion Gene Using a Combination of Droplet-Reverse Transcription-Polymerase Chain Reaction and Instant-Quality Fluorescence in Situ Hybridization","volume":"453","author":"Shigeto","year":"2016","journal-title":"Clin. Chim. Acta"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jmoldx.2013.04.007","article-title":"BCR-ABL1 RT-qPCR for Monitoring the Molecular Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia","volume":"15","author":"Press","year":"2013","journal-title":"J. Mol. Diagn."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/s41375-022-01612-2","article-title":"Impact of BCR::ABL1 Transcript Type on RT-qPCR Amplification Performance and Molecular Response to Therapy","volume":"36","author":"Salmon","year":"2022","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3324\/haematol.2009.011346","article-title":"Clinical Features and Prognostic Implications of TCF3-PBX1 and ETV6-RUNX1 in Adult Acute Lymphoblastic Leukemia","volume":"95","author":"Burmeister","year":"2010","journal-title":"Haematologica"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1038\/sj.leu.2402730","article-title":"Comparison of Competitive-Nested PCR and Real-Time PCR in Detecting BCR-ABL Fusion Transcripts in Chronic Myeloid Leukemia Patients","volume":"16","author":"Guo","year":"2002","journal-title":"Leukemia"},{"key":"ref_66","first-page":"1411","article-title":"Application of a New Protocol for Nested PCR to the Detection of Minimal Residual Bcr\/Abl Transcripts","volume":"8","author":"Frenoy","year":"1994","journal-title":"Leukemia"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/dna4030019","article-title":"Nested-PCR vs. RT-qPCR: A Sensitivity Comparison in the Detection of Genetic Alterations in Patients with Acute Leukemias","volume":"4","author":"Pessoa","year":"2024","journal-title":"DNA"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Ip, B.B.K., Wong, A.T.C., Law, J.H.Y., Au, C.H., Ma, S.Y., Chim, J.C.S., Liang, R.H.S., Leung, A.Y.H., Wan, T.S.K., and Ma, E.S.K. (2024). Application of Droplet Digital PCR in Minimal Residual Disease Monitoring of Rare Fusion Transcripts and Mutations in Haematological Malignancies. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-57016-y"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s12185-022-03402-z","article-title":"Droplet Digital PCR for Genetic Mutations Monitoring Predicts Relapse Risk in Pediatric Acute Myeloid Leukemia","volume":"116","author":"Chen","year":"2022","journal-title":"Int. J. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"112","DOI":"10.31768\/2312-8852.2016.38(2):112-116","article-title":"Detection of notch1 C.7544_7545delct mutation in chronic lymphocytic leukemia using conventional and real-time polymerase chain reaction","volume":"38","author":"Bilous","year":"2016","journal-title":"Exp. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1038\/jid.2013.1","article-title":"Research Techniques Made Simple: Polymerase Chain Reaction (PCR)","volume":"133","author":"Garibyan","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_72","unstructured":"Ghannam, M.G., and Varacallo, M.A. (2025). Biochemistry, Polymerase Chain Reaction. StatPearls, StatPearls Publishing."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Li, W. (2022). Flow Cytometry in the Diagnosis of Leukemias. Leukemia, Exon Publications.","DOI":"10.36255\/exon-publications-leukemia-flow-cytometry"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"119945","DOI":"10.1016\/j.cca.2024.119945","article-title":"Flow Cytometry in Acute Myeloid Leukemia and Detection of Minimal Residual Disease","volume":"564","author":"Cai","year":"2025","journal-title":"Clin. Chim. Acta"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Ally, F., and Chen, X. (2024). Acute Myeloid Leukemia: Diagnosis and Evaluation by Flow Cytometry. Cancers, 16.","DOI":"10.3390\/cancers16223855"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Sukumaran, R., Nair, R.A., Jacob, P.M., Nair Anila, K.A.R., Prem, S., Binitha, R., and Kusumakumary, P. (2015). Flow Cytometric Analysis of Mixed Phenotype Acute Leukemia: Experience from a Tertiary Oncology Center. Indian J. Pathol. Microbiol., 58.","DOI":"10.4103\/0377-4929.155309"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Kruse, A., Abdel-Azim, N., Kim, H.N., Ruan, Y., Phan, V., Ogana, H., Wang, W., Lee, R., Gang, E.J., and Khazal, S. (2020). Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21031054"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cll.2017.07.003","article-title":"Acute Myeloid Leukemia Immunophenotyping by Flow Cytometric Analysis","volume":"37","author":"Chen","year":"2017","journal-title":"Clin. Lab. Med."},{"key":"ref_79","first-page":"149","article-title":"Advances and Issues in Flow Cytometric Detection of Immunophenotypic Changes and Genomic Rearrangements in Acute Pediatric Leukemia","volume":"3","author":"Wang","year":"2014","journal-title":"Transl. Pediatr."},{"key":"ref_80","unstructured":"Kala, P.S., and Zubair, M. (2025). Flow Cytometry Blood Cell Identification. StatPearls, StatPearls Publishing."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Smith, A.C., Hoischen, A., and Raca, G. (2023). Cytogenetics Is a Science, Not a Technique! Why Optical Genome Mapping Is So Important to Clinical Genetic Laboratories. Cancers, 15.","DOI":"10.3390\/cancers15225470"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Wiedmeier-Nutor, J.E., McCabe, C.E., O\u2019Brien, D.R., Jessen, E., Bonolo de Campos, C., Boddicker, N.J., Griffin, R., Allmer, C., Rabe, K.G., and Cerhan, J.R. (2024). Utility of Targeted Sequencing Compared to FISH for Detection of Chronic Lymphocytic Leukemia Copy Number Alterations. Cancers, 16.","DOI":"10.3390\/cancers16132450"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"242","DOI":"10.21037\/atm.2018.05.30","article-title":"Diagnostic Molecular Techniques in Haematology: Recent Advances","volume":"6","author":"Koutsi","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"100534","DOI":"10.1016\/j.modpat.2024.100534","article-title":"Clonal Dynamics and Relapse Risk Revealed by High-Sensitivity FLT3-Internal Tandem Duplication Detection in Acute Myeloid Leukemia","volume":"37","author":"Oduro","year":"2024","journal-title":"Mod. Pathol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1182\/bloodadvances.2020002517","article-title":"Challenging Conventional Karyotyping by Next-Generation Karyotyping in 281 Intensively Treated Patients with AML","volume":"5","author":"Mareschal","year":"2021","journal-title":"Blood Adv."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/gcc.22806","article-title":"Clonal Evolution of Acute Myeloid Leukemia from Diagnosis to Relapse","volume":"58","author":"Vosberg","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"71234","DOI":"10.18632\/oncotarget.19525","article-title":"Next-Generation Sequencing in Chronic Lymphocytic Leukemia: Recent Findings and New Horizons","volume":"8","author":"Bikos","year":"2017","journal-title":"Oncotarget"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jmoldx.2018.09.009","article-title":"Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics","volume":"21","author":"Alonso","year":"2019","journal-title":"J. Mol. Diagn."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Madaci, L., Farnault, L., Abbou, N., Gabert, J., Venton, G., and Costello, R. (2023). Impact of Next-Generation Sequencing in Diagnosis, Prognosis and Therapeutic Management of Acute Myeloid Leukemia\/Myelodysplastic Neoplasms. Cancers, 15.","DOI":"10.3390\/cancers15133280"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jmoldx.2019.08.002","article-title":"A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients","volume":"22","author":"Corchete","year":"2020","journal-title":"J. Mol. Diagn."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41408-018-0148-6","article-title":"Challenges in the Introduction of Next-Generation Sequencing (NGS) for Diagnostics of Myeloid Malignancies into Clinical Routine Use","volume":"8","author":"Bacher","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-019-0815-5","article-title":"Next-Generation Sequencing for BCR-ABL1 Kinase Domain Mutation Testing in Patients with Chronic Myeloid Leukemia: A Position Paper","volume":"12","author":"Soverini","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"8957","DOI":"10.4081\/hr.2020.8957","article-title":"Advancing Leukemia Diagnostics: Role of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia","volume":"12","author":"Haferlach","year":"2020","journal-title":"Hematol. Rep."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Coccaro, N., Anelli, L., Zagaria, A., Specchia, G., and Albano, F. (2019). Next-Generation Sequencing in Acute Lymphoblastic Leukemia. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20122929"},{"key":"ref_95","first-page":"612","article-title":"Research Progress of Next Generation Sequencing in Acute Leukemia\u2014Review","volume":"31","author":"Chen","year":"2023","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jmoldx.2023.01.009","article-title":"Next-CLL, a New Next-Generation Sequencing\u2013Based Method for Assessment of IGHV Gene Mutational Status in Chronic Lymphoid Leukemia","volume":"25","author":"Bourbon","year":"2023","journal-title":"J. Mol. Diagn."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"108471","DOI":"10.1016\/j.mrrev.2023.108471","article-title":"Next-Generation Sequencing Methodologies To Detect Low-Frequency Mutations: Catch Me If You Can","volume":"792","author":"Menon","year":"2023","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/gim.2015.121","article-title":"Capture-Based High-Coverage NGS: A Powerful Tool to Uncover a Wide Spectrum of Mutation Types","volume":"18","author":"Wang","year":"2016","journal-title":"Genet. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3324\/haematol.2018.205955","article-title":"Next-Generation Sequencing in the Diagnosis and Minimal Residual Disease Assessment of Acute Myeloid Leukemia","volume":"104","author":"Levine","year":"2019","journal-title":"Haematologica"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Chaudhary, P., Chaudhary, S., Patel, F., Patel, S., Vaishnani, T., Trivedi, N., Patel, D., Sonagara, T., Hirapara, A., and Vyas, K. (2024). Validation of a Novel NGS Based BCR::ABL1 Kinase Domain Mutation Detection Assay in Indian Cohort. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-66310-8"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1182\/blood-2018-99-114130","article-title":"Mutational Phasing: Clinical Relevance in Tyrosine Kinase Domain Mutations Using Next Generation Sequencing in Chronic Myeloid Leukemia","volume":"132","author":"Bhatwadekar","year":"2018","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Satam, H., Joshi, K., Mangrolia, U., Waghoo, S., Zaidi, G., Rawool, S., Thakare, R.P., Banday, S., Mishra, A.K., and Das, G. (2023). Next-Generation Sequencing Technology: Current Trends and Advancements. Biology, 12.","DOI":"10.3390\/biology12070997"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/s41375-022-01806-8","article-title":"Whole Genome Sequencing Provides Comprehensive Genetic Testing in Childhood B-Cell Acute Lymphoblastic Leukaemia","volume":"37","author":"Ryan","year":"2023","journal-title":"Leukemia"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"17","DOI":"10.19156\/cbn.2016.0004","article-title":"Next Generation Sequencing (NGS) in Oncology: Lights and Shadows","volume":"4","author":"Nannini","year":"2016","journal-title":"CBN"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2015-10-674572","article-title":"Whole-Exome Sequencing in Relapsing Chronic Lymphocytic Leukemia: Clinical Impact of Recurrent RPS15 Mutations","volume":"127","author":"Cortese","year":"2016","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/jhg.2013.114","article-title":"The Promise of Whole-Exome Sequencing in Medical Genetics","volume":"59","author":"Rabbani","year":"2014","journal-title":"J. Hum. Genet."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"42345","DOI":"10.18632\/oncotarget.5645","article-title":"IDH1\/2 but Not DNMT3A Mutations Are Suitable Targets for Minimal Residual Disease Monitoring in Acute Myeloid Leukemia Patients: A Study by the Acute Leukemia French Association","volume":"6","author":"Debarri","year":"2015","journal-title":"Oncotarget"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"102033","DOI":"10.18632\/oncotarget.22116","article-title":"Development and Validation of a Targeted next Generation DNA Sequencing Panel Outperforming Whole Exome Sequencing for the Identification of Clinically Relevant Genetic Variants","volume":"8","author":"Miller","year":"2017","journal-title":"Oncotarget"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Ahmed, F., and Zhong, J. (2024). Advances in DNA\/RNA Sequencing and Their Applications in Acute Myeloid Leukemia (AML). Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26010071"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Petiti, J., Pignochino, Y., Schiavon, A., Giugliano, E., Berrino, E., Giordano, G., Itri, F., Dragani, M., Cilloni, D., and Lo Iacono, M. (2024). Comprehensive Molecular Profiling of NPM1-Mutated Acute Myeloid Leukemia Using RNAseq Approach. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25073631"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/s41588-023-01429-4","article-title":"Transcriptomic Classes of BCR-ABL1 Lymphoblastic Leukemia","volume":"55","author":"Kim","year":"2023","journal-title":"Nat. Genet."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"CT112","DOI":"10.1158\/1538-7445.AM2015-CT112","article-title":"Abstract CT112: Implementation of CLIA Enabled Integrated Whole Genome (WGS)\/Exome (WES)\/Transcriptome (RNAseq) next-Gen Sequencing to Identify Therapeutically Relevant Targets in Advanced Cancer Patients","volume":"75","author":"Borad","year":"2015","journal-title":"Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"100540","DOI":"10.1016\/j.esmoop.2022.100540","article-title":"Comparison of Actionable Events Detected in Cancer Genomes by Whole-Genome Sequencing, in Silico Whole-Exome and Mutation Panels","volume":"7","author":"Kondrashova","year":"2022","journal-title":"ESMO Open"},{"key":"ref_114","first-page":"87","article-title":"An NGS Workflow Blueprint for DNA Sequencing Data and Its Application in Individualized Molecular Oncology","volume":"14","author":"Li","year":"2016","journal-title":"Cancer Inform."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Vicente-Garc\u00e9s, C., Esperanza-Cebollada, E., Montesdeoca, S., Torrebadell, M., Rives, S., Dapena, J.L., Catal\u00e0, A., Conde, N., Cam\u00f3s, M., and Vega-Garc\u00eda, N. (2022). Technical Validation and Clinical Utility of an NGS Targeted Panel to Improve Molecular Characterization of Pediatric Acute Leukemia. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.854098"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Singh, R.R. (2022). Target Enrichment Approaches for Next-Generation Sequencing Applications in Oncology. Diagnosis, 12.","DOI":"10.3390\/diagnostics12071539"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"110842","DOI":"10.1016\/j.ygeno.2024.110842","article-title":"Advancements in Long-Read Genome Sequencing Technologies and Algorithms","volume":"116","author":"Espinosa","year":"2024","journal-title":"Genomics"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2021-148012","article-title":"A Novel NGS-Based Simultaneous Detection of DNA and RNA Biomarkers Using Total Nucleic Acid (TNA) for Acute Lymphocytic Leukemia (ALL)","volume":"138","author":"Ramesh","year":"2021","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: The Catalogue Of Somatic Mutations In Cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","article-title":"COSMIC: A Curated Database of Somatic Variants and Clinical Data for Cancer","volume":"52","author":"Sondka","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Gil, J.V., Such, E., Sargas, C., Simarro, J., Miralles, A., P\u00e9rez, G., De Juan, I., Palanca, S., Avetisyan, G., and Santiago, M. (2023). Design and Validation of a Custom Next-Generation Sequencing Panel in Pediatric Acute Lymphoblastic Leukemia. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054440"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Inaba, H., Azzato, E.M., and Mullighan, C.G. (2017). Integration of Next-Generation Sequencing to Treat Acute Lymphoblastic Leukemia with Targetable Lesions: The St. Jude Children\u2019s Research Hospital Approach. Front. Pediatr., 5.","DOI":"10.3389\/fped.2017.00258"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/gcc.22464","article-title":"ETV6\/RUNX1-like Acute Lymphoblastic Leukemia: A Novel B-Cell Precursor Leukemia Subtype Associated with the CD27\/CD44 Immunophenotype","volume":"56","author":"Zaliova","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Paolino, J., Tsai, H.K., Harris, M.H., and Pikman, Y. (2024). IKZF1 Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia. Biomedicines, 12.","DOI":"10.3390\/biomedicines12010089"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41416-023-02294-y","article-title":"\u2018Evaluation of Adverse Prognostic Gene Alterations & MRD Positivity in BCR::ABL1-like B-Lineage Acute Lymphoblastic Leukaemia Patients, in a Resource-Constrained Setting","volume":"129","author":"Gupta","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00277-023-05241-2","article-title":"Philadelphia-like Acute Lymphoblastic Leukemia: The Journey from Molecular Background to the Role of Bone Marrow Transplant\u2014Review Article","volume":"102","author":"Alghandour","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3324\/haematol.2011.056135","article-title":"IKZF1 Deletion Is an Independent Predictor of Outcome in Pediatric Acute Lymphoblastic Leukemia Treated According to the ALL-BFM 2000 Protocol","volume":"98","author":"Meissner","year":"2013","journal-title":"Haematologica"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/leu.2010.87","article-title":"IKZF1 Deletions Predict Relapse in Uniformly Treated Pediatric Precursor B-ALL","volume":"24","author":"Kuiper","year":"2010","journal-title":"Leukemia"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1182\/blood.2019000813","article-title":"IKZF1 Deletions in Pediatric Acute Lymphoblastic Leukemia: Still a Poor Prognostic Marker?","volume":"135","author":"Stanulla","year":"2020","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/08880018.2021.1966558","article-title":"Quantitative Analysis of IKZF1 Gene Deletions in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia: Higher Levels Are Associated with a Poorer Prognosis","volume":"39","author":"Huang","year":"2022","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/leu.2015.134","article-title":"IKZF1 Deletion Is an Independent Prognostic Marker in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia, and Distinguishes Patients Benefiting from Pulses during Maintenance Therapy: Results of the EORTC Children\u2019s Leukemia Group Study 58951","volume":"29","author":"Clappier","year":"2015","journal-title":"Leukemia"},{"key":"ref_132","first-page":"3904","article-title":"IKZF1 Gene Deletions Drive Resistance to Cytarabine in B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"109","author":"Vervoort","year":"2024","journal-title":"Haematologica"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.leukres.2008.11.001","article-title":"Cluster Analysis of Genomic ETV6\u2013RUNX1 (TEL\u2013AML1) Fusion Sites in Childhood Acute Lymphoblastic Leukemia","volume":"33","author":"Jacobs","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1182\/blood-2017-09-808402","article-title":"Five Percent of Healthy Newborns Have an ETV6-RUNX1 Fusion as Revealed by DNA-Based GIPFEL Screening","volume":"131","author":"Olsen","year":"2018","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1182\/blood-2011-02-338848","article-title":"Modeling the Evolution of ETV6-RUNX1-Induced B-Cell Precursor Acute Lymphoblastic Leukemia in Mice","volume":"118","author":"Giotopoulos","year":"2011","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1158\/0008-5472.CAN-17-0701","article-title":"Infection Exposure Promotes ETV6-RUNX1 Precursor B-Cell Leukemia via Impaired H3K4 Demethylases","volume":"77","author":"Hauer","year":"2017","journal-title":"Cancer Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.exphem.2019.03.004","article-title":"ETV6-RUNX1 Interacts with a Region in SPIB Intron 1 to Regulate Gene Expression in Pre-B-Cell Acute Lymphoblastic Leukemia","volume":"73","author":"Xu","year":"2019","journal-title":"Exp. Hematol."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Zerella, J.R., Homan, C.C., Arts, P., Brown, A.L., Scott, H.S., and Hahn, C.N. (2023). Transcription Factor Genetics and Biology in Predisposition to Bone Marrow Failure and Hematological Malignancy. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1183318"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"446","DOI":"10.4143\/crt.2016.211","article-title":"Outcome and Prognostic Factors for ETV6\/RUNX1 Positive Pediatric Acute Lymphoblastic Leukemia Treated at a Single Institution in Korea","volume":"49","author":"Lee","year":"2017","journal-title":"Cancer Res. Treat."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Meyer, L.K., Delgado-Martin, C., Maude, S.L., Shannon, K.M., Teachey, D.T., and Hermiston, M.L. (2019). CRLF2 Rearrangement in Ph-like Acute Lymphoblastic Leukemia Predicts Relative Glucocorticoid Resistance That Is Overcome with MEK or Akt Inhibition. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0220026"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1615\/CritRevOncog.v16.i1-2.30","article-title":"Understanding the Biology of CRLF2-Overexpressing Acute Lymphoblastic Leukemia","volume":"16","author":"Tasian","year":"2011","journal-title":"Crit. Rev. Oncog."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","article-title":"Rearrangement of CRLF2 Is Associated with Mutation of JAK Kinases, Alteration of IKZF1, Hispanic\/Latino Ethnicity, and a Poor Outcome in Pediatric B-Progenitor Acute Lymphoblastic Leukemia","volume":"115","author":"Harvey","year":"2010","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2011-12-389932","article-title":"Aberrant STAT5 and PI3K\/mTOR Pathway Signaling Occurs in Human CRLF2-Rearranged B-Precursor Acute Lymphoblastic Leukemia","volume":"120","author":"Tasian","year":"2012","journal-title":"Blood"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"100741","DOI":"10.1016\/j.modpat.2025.100741","article-title":"Molecular Profiling Reveals Novel Gene Fusions and Genetic Markers for Refined Patient Stratification in Pediatric Acute Lymphoblastic Leukemia","volume":"38","author":"Egyed","year":"2025","journal-title":"Mod. Pathol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood.2023023754","article-title":"NGS-Based Stratification Refines the Risk Stratification in T-ALL and Identifies a Very-High-Risk Subgroup of Patients","volume":"144","author":"Simonin","year":"2024","journal-title":"Blood"},{"key":"ref_146","first-page":"e10696","article-title":"Integration of Next-Generation Sequencing in Diagnosing and Minimal Residual Disease Detection in Patients With Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia","volume":"12","author":"Sherali","year":"2020","journal-title":"Cureus"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.clml.2023.11.002","article-title":"Concordance of Next-Generation Sequencing and Multiparametric Flow Cytometry Methods for Detecting Measurable Residual Disease in Adult Acute Lymphoblastic Leukemia: Optimizing Prediction of Clinical Outcomes From a Single-Center Study","volume":"24","author":"Ashouri","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1182\/blood-2021-152369","article-title":"Performance of Next Generation Sequencing for Minimal Residual Disease Detection for Pediatric Patients with Acute Lymphoblastic Leukemia: Results from the Prospective Clinical Trial DFCI 16-001","volume":"138","author":"Paolino","year":"2021","journal-title":"Blood"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Krstevska Bozhinovikj, E., Matevska-Geshkovska, N., Staninova Stojovska, M., Gjorgievska, E., Jovanovska, A., Ridova, N., Panovska Stavridis, I., Kocheva, S., and Dimovski, A. (2025). Presence of Minimal Residual Disease Determined by Next-Generation Sequencing Is Not a Reliable Prognostic Biomarker in Children with Acute Lymphoblastic Leukemia. Leuk. Lymphoma, 1\u20138.","DOI":"10.1080\/10428194.2025.2456100"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1097\/MPH.0000000000001772","article-title":"The Application of Next-Generation Sequencing Tumor Molecular Profiling in the Diagnosis and Management of a Case of Acute Myelogenous Leukemia With MLL-PTD in a Pediatric Heart Transplant Recipient","volume":"43","author":"Woolbright","year":"2021","journal-title":"J. Pediatr. Hematol.\/Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Mosquera Orgueira, A., Peleteiro Ra\u00edndo, A., Cid L\u00f3pez, M., Antelo Rodr\u00edguez, B., D\u00edaz Arias, J.\u00c1., Ferreiro Ferro, R., Alonso Vence, N., Benda\u00f1a L\u00f3pez, \u00c1., Abu\u00edn Blanco, A., and Bao P\u00e9rez, L. (2021). Gene Expression Profiling Identifies FLT3 Mutation-like Cases in Wild-Type FLT3 Acute Myeloid Leukemia. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0247093"},{"key":"ref_152","first-page":"6766","article-title":"Prognosis and Outcome of Patients with Acute Myeloid Leukemia Based on FLT3-ITD Mutation with or without Additional Abnormal Cytogenetics","volume":"18","author":"Tao","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3109\/10428194.2013.840776","article-title":"Mutated Nucleophosmin-1 (NPM1) in Patients with Acute Myeloid Leukemia (AML) in Remission and Relapse","volume":"55","author":"Jain","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1200\/JCO.2009.25.1496","article-title":"Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study","volume":"28","author":"Becker","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5045\/br.2019.54.3.189","article-title":"Favorable Long-Term Survival Using Consolidation Chemotherapy without Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia with Wild-Type NPM1 without FLT3-ITD","volume":"54","author":"Baek","year":"2019","journal-title":"Blood Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2022008316","article-title":"Clinical Outcomes Associated with NPM1 Mutations in Patients with Relapsed or Refractory AML","volume":"7","author":"Issa","year":"2022","journal-title":"Blood Adv."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1182\/blood-2007-05-092510","article-title":"Internal Tandem Duplication of FLT3 (FLT3\/ITD) Induces Increased ROS Production, DNA Damage, and Misrepair: Implications for Poor Prognosis in AML","volume":"111","author":"Sallmyr","year":"2008","journal-title":"Blood"},{"key":"ref_158","first-page":"1811","article-title":"Fms like Tyrosine Kinase (FLT3) and Nucleophosmin 1 (NPM1) Mutations in de Novo Normal Karyotype Acute Myeloid Leukemia (AML)","volume":"11","author":"Dunna","year":"2010","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1182\/blood-2024-208119","article-title":"The Prognostic Impact of Other Somatic Mutations and Cytogenetic Abnormalities in Patients with NPM1 and\/or FLT3-ITD Mutated AML in the Era of FLT3-Inhibitors: Real-Life Data from the Greek AML Registry","volume":"144","author":"Lazana","year":"2024","journal-title":"Blood"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1158\/1078-0432.CCR-12-1773","article-title":"IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives","volume":"18","author":"Yang","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.humpath.2012.05.003","article-title":"IDH Mutations in Acute Myeloid Leukemia","volume":"43","author":"Rakheja","year":"2012","journal-title":"Human Pathol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/ajh.26694","article-title":"Contemporary Outcomes in -Mutated Acute Myeloid Leukemia: The Impact of Co-Occurring Mutations and Venetoclax-Based Treatment","volume":"97","author":"Lachowiez","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s12288-016-0649-z","article-title":"Prevalence and Prognostic Value of IDH1 R132 Mutation in Newly Diagnosed AML Egyptian Patients with Normal Karyotype","volume":"33","author":"Salem","year":"2017","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2009-11-250878","article-title":"Acquired Mutations in the Genes Encoding IDH1 and IDH2 Both Are Recurrent Aberrations in Acute Myeloid Leukemia: Prevalence and Prognostic Value","volume":"116","author":"Abbas","year":"2010","journal-title":"Blood"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-021-00497-1","article-title":"Acute Myeloid Leukemia with IDH1 and IDH2 Mutations: 2021 Treatment Algorithm","volume":"11","author":"Issa","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1038\/s41467-021-22874-x","article-title":"Leukemia Stemness and Co-Occurring Mutations Drive Resistance to IDH Inhibitors in Acute Myeloid Leukemia","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Kowalczyk, A., Zarychta, J., Lejman, M., Latoch, E., and Zawitkowska, J. (2024). Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors\u2014Recent Advances, Challenges and Future Prospects. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25147916"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2217\/ijh-2016-0011","article-title":"Targeted Therapies in the Treatment of Adult Acute Myeloid Leukemias: Current Status and Future Perspectives","volume":"5","author":"Castelli","year":"2016","journal-title":"Int. J. Hematol. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40291-019-00443-9","article-title":"Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia","volume":"24","author":"Yang","year":"2020","journal-title":"Mol. Diagn. Ther."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Fedorov, K., Maiti, A., and Konopleva, M. (2023). Targeting FLT3 Mutation in Acute Myeloid Leukemia: Current Strategies and Future Directions. Cancers, 15.","DOI":"10.3390\/cancers15082312"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3324\/haematol.2018.191148","article-title":"Persistent IDH1\/2 Mutations in Remission Can Predict Relapse in Patients with Acute Myeloid Leukemia","volume":"104","author":"Ok","year":"2019","journal-title":"Haematologica"},{"key":"ref_172","first-page":"134","article-title":"Next Generation Sequencing Guided Treatment Modulation and Prognosis in Acute Myeloid Leukemia: Case Vignettes","volume":"10","author":"Jain","year":"2020","journal-title":"Am. J. Blood Res."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3343\/alm.2023.43.4.328","article-title":"Development of a Next-Generation Sequencing-Based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia","volume":"43","author":"Kim","year":"2023","journal-title":"Ann. Lab. Med."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.3109\/10428194.2014.898760","article-title":"NOTCH1, SF3B1, BIRC3 and TP53 Mutations in Patients with Chronic Lymphocytic Leukemia Undergoing First-Line Treatment: Correlation with Biological Parameters and Response to Treatment","volume":"55","author":"Chiaretti","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/ijc.30222","article-title":"TP53 Mutations Are Early Events in Chronic Lymphocytic Leukemia Disease Progression and Precede Evolution to Complex Karyotypes","volume":"139","author":"Lazarian","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/leu.2010.208","article-title":"TP53 Mutation Profile in Chronic Lymphocytic Leukemia: Evidence for a Disease Specific Profile from a Comprehensive Analysis of 268 Mutations","volume":"24","author":"Zenz","year":"2010","journal-title":"Leukemia"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1158\/1078-0432.CCR-20-4890","article-title":"Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib","volume":"27","author":"Brieghel","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1200\/JCO.2010.32.0838","article-title":"Mutational Status of the TP53 Gene as a Predictor of Response and Survival in Patients with Chronic Lymphocytic Leukemia: Results from the LRF CLL4 Trial","volume":"29","author":"Gonzalez","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5603\/AHP.2021.0012","article-title":"TP53 Mutations in Chronic Lymphocytic Leukemia","volume":"52","author":"Robak","year":"2021","journal-title":"Acta Haematol. Pol."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"F\u00fcrstenau, M., and Eichhorst, B. (2021). Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance. Cancers, 13.","DOI":"10.3390\/cancers13061336"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/hon.3063","article-title":"The Spectrum of Subclonal TP53 Mutations in Chronic Lymphocytic Leukemia: A next Generation Sequencing Retrospective Study","volume":"40","author":"Cerruti","year":"2022","journal-title":"Hematol. Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41375-017-0007-7","article-title":"ERIC Recommendations for TP53 Mutation Analysis in Chronic Lymphocytic Leukemia\u2014Update on Methodological Approaches and Results Interpretation","volume":"32","author":"Malcikova","year":"2018","journal-title":"Leukemia"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3324\/haematol.2018.187583","article-title":"TP53 Aberrations in Chronic Lymphocytic Leukemia: An Overview of the Clinical Implications of Improved Diagnostics","volume":"103","author":"Campo","year":"2018","journal-title":"Haematologica"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jmoldx.2020.01.008","article-title":"Ultrasensitive Detection of NOTCH1 c.7544_7545delCT Mutations in Chronic Lymphocytic Leukemia by Droplet Digital PCR Reveals High Frequency of Subclonal Mutations and Predicts Clinical Outcome in Cases with Trisomy 12","volume":"22","author":"Hoofd","year":"2020","journal-title":"J. Mol. Diagn."},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Willander, K., Dutta, R.K., Ungerb\u00e4ck, J., Gunnarsson, R., Juliusson, G., Fredrikson, M., Linderholm, M., and S\u00f6derkvist, P. (2013). NOTCH1 Mutations Influence Survival in Chronic Lymphocytic Leukemia Patients. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-274"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"106827","DOI":"10.1016\/j.leukres.2022.106827","article-title":"Landscape of NOTCH1 Mutations and Co-Occurring Biomarker Alterations in Chronic Lymphocytic Leukemia","volume":"116","author":"Jelloul","year":"2022","journal-title":"Leuk. Res."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/leu.2012.357","article-title":"NOTCH1 Mutations Identify a Genetic Subgroup of Chronic Lymphocytic Leukemia Patients with High Risk of Transformation and Poor Outcome","volume":"27","author":"Villamor","year":"2013","journal-title":"Leukemia"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2011-09-379966","article-title":"Mutations of NOTCH1 Are an Independent Predictor of Survival in Chronic Lymphocytic Leukemia","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood"},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Pozzo, F., Bittolo, T., Tissino, E., Zucchetto, A., Bomben, R., Polcik, L., Dannewitz Prosseda, S., Hartmann, T.N., and Gattei, V. (2022). Multiple Mechanisms of NOTCH1 Activation in Chronic Lymphocytic Leukemia: NOTCH1 Mutations and Beyond. Cancers, 14.","DOI":"10.3390\/cancers14122997"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"69916","DOI":"10.18632\/oncotarget.19455","article-title":"SF3B1 Mutation Is a Prognostic Factor in Chronic Lymphocytic Leukemia: A Meta-Analysis","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood-2012-09-399725","article-title":"Biologic and Clinical Significance of Somatic Mutations of SF3B1 in Myeloid and Lymphoid Neoplasms","volume":"121","author":"Cazzola","year":"2013","journal-title":"Blood"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1182\/blood-2013-02-427641","article-title":"SF3B1 Mutations in Chronic Lymphocytic Leukemia","volume":"121","author":"Wan","year":"2013","journal-title":"Blood"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ccell.2016.10.005","article-title":"Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia","volume":"30","author":"Wang","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1182\/blood-2011-08-373159","article-title":"Mutations of the SF3B1 Splicing Factor in Chronic Lymphocytic Leukemia: Association with Progression and Fludarabine-Refractoriness","volume":"118","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","article-title":"SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia","volume":"365","author":"Wang","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/j.seminhematol.2024.01.009","article-title":"The Molecular Map of CLL and Richter\u2019s Syndrome","volume":"61","author":"Sud","year":"2024","journal-title":"Semin. Hematol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"176","DOI":"10.21037\/atm.2019.03.63","article-title":"SF3B1 Mutation Predicts Unfavorable Treatment-Free Survival in Chinese Chronic Lymphocytic Leukemia Patients","volume":"7","author":"Miao","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"104243","DOI":"10.1016\/j.drudis.2024.104243","article-title":"Efficacy and Challenges Involving Combination Therapies in CLL","volume":"29","author":"Alanazi","year":"2024","journal-title":"Drug Discov. Today"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","article-title":"Clinical Impact of Clonal and Subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM Mutations in Chronic Lymphocytic Leukemia","volume":"127","author":"Nadeu","year":"2016","journal-title":"Blood"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood.2024026672","article-title":"Novel Mechanisms of Resistance in CLL: Variant BTK Mutations in Second-Generation and Noncovalent BTK Inhibitors","volume":"145","author":"Tam","year":"2025","journal-title":"Blood"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/14656566.2023.2218545","article-title":"An Update on the Efficacy of Venetoclax for Chronic Lymphocytic Leukemia","volume":"24","author":"Lovell","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.1182\/blood-2019-124693","article-title":"Predictive Significance of Selected Gene Mutations Identified Using Next Generation Sequencing in Relapsed and Refractory Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib","volume":"134","author":"Machnicki","year":"2019","journal-title":"Blood"},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Brown, J., Mashima, K., Fernandes, S., Naeem, A., Shupe, S., Fardoun, R., and Davids, M. (2024). Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in CLL. Res. Sq.","DOI":"10.21203\/rs.3.rs-3837426\/v1"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood-2023-178819","article-title":"Extended Follow-up and Resistance Mutations in CLL Patients Treated with Acalabrutinib","volume":"142","author":"Sun","year":"2023","journal-title":"Blood"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2019002969","article-title":"Prospective Assessment of NGS-Detectable Mutations in CML Patients with Nonoptimal Response: The NEXT-in-CML Study","volume":"135","author":"Soverini","year":"2020","journal-title":"Blood"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/HS9.0000000000000199","article-title":"NGS in CML\u2014New Standard Diagnostic Procedure?","volume":"3","author":"Branford","year":"2019","journal-title":"Hemasphere"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"8486267","DOI":"10.1155\/2024\/8486267","article-title":"A Novel BCR::ABL1 Variant Detected with Multiple Testing Modalities","volume":"2024","author":"Jean","year":"2024","journal-title":"Case Rep. Hematol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","article-title":"European LeukemiaNet Laboratory Recommendations for the Diagnosis and Management of Chronic Myeloid Leukemia","volume":"37","author":"Cross","year":"2023","journal-title":"Leukemia"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cancergen.2023.08.099","article-title":"91. Atypical BCR::ABL1 Rearrangements Identified by Optical Genome Mapping in Patients with Chronic Myeloid Leukemia","volume":"278\u2013279","author":"Sahoo","year":"2023","journal-title":"Cancer Genet."},{"key":"ref_210","first-page":"9071702","article-title":"Chronic Myeloid Leukemia with an E6a2 BCR-ABL1 Fusion Transcript: Cooperating Mutations at Blast Crisis and Molecular Monitoring","volume":"2017","author":"Crampe","year":"2017","journal-title":"Case Rep. Hematol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"e2020062","DOI":"10.4084\/mjhid.2020.062","article-title":"Prognostic Significance of Transcript-Type BCR\u2014ABL1 in Chronic Myeloid Leukemia","volume":"12","author":"Molica","year":"2020","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"9439134","DOI":"10.1155\/2024\/9439134","article-title":"Diagnostic Ambiguity Caused by an Atypical E18a2 BCR::ABL1 Transcript in a Chronic Myeloid Leukemia Patient","volume":"2024","author":"Pretzsch","year":"2024","journal-title":"Case Rep. Hematol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3324\/haematol.2013.096537","article-title":"Distinct Characteristics of E13a2 versus E14a2 BCR-ABL1 Driven Chronic Myeloid Leukemia under First-Line Therapy with Imatinib","volume":"99","author":"Hanfstein","year":"2014","journal-title":"Haematologica"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2353\/jmoldx.2009.090008","article-title":"A Rare E14a3 (B3a3) BCR-ABL Fusion Transcript in Chronic Myeloid Leukemia: Diagnostic Challenges in Clinical Laboratory Practice","volume":"11","author":"Jinawath","year":"2009","journal-title":"J. Mol. Diagn."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41375-024-02314-7","article-title":"The E13a3 (B2a3) and E14a3 (B3a3) BCR::ABL1 Isoforms Are Resistant to Asciminib","volume":"38","author":"Leske","year":"2024","journal-title":"Leukemia"},{"key":"ref_216","first-page":"458716","article-title":"Chronic Myeloid Leukemia with E19a2 BCR-ABL1 Transcripts and Marked Thrombocytosis: The Role of Molecular Monitoring","volume":"2012","author":"Langabeer","year":"2012","journal-title":"Case Rep. Hematol."},{"key":"ref_217","first-page":"785","article-title":"Variant E19a2 BCR-ABL1 Fusion Transcript in Typical Chronic Myeloid Leukemia","volume":"57","author":"Chirieac","year":"2011","journal-title":"Clin. Lab."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jmsacl.2023.04.002","article-title":"A Customized Mass Array Panel for BCR::ABL1 Tyrosine Kinase Domain Mutation Screening in Chronic Myeloid Leukemia","volume":"28","author":"Limsuwanachot","year":"2023","journal-title":"J. Mass Spectrom. Adv. Clin. Lab"},{"key":"ref_219","doi-asserted-by":"crossref","unstructured":"Tanneeru, K., and Guruprasad, L. (2013). Ponatinib Is a Pan-BCR-ABL Kinase Inhibitor: MD Simulations and SIE Study. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0078556"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"27","DOI":"10.31861\/biosystems2019.01.027","article-title":"Characteristics of BCR\/ABL1 Kinase Domain Mutations in the Patients with Chronic Myeloid Leukemia Who Are Primary Resistant to the Imatinib Therapy","volume":"11","author":"Dmytrenko","year":"2019","journal-title":"Biosystems"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.hoc.2011.09.004","article-title":"Chronic Myeloid Leukemia\u2014Mechanisms of Resistance and Treatment","volume":"25","author":"Jabbour","year":"2011","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_222","doi-asserted-by":"crossref","unstructured":"Alves, R., Gon\u00e7alves, A.C., Rutella, S., Almeida, A.M., De Las Rivas, J., Trougakos, I.P., and Sarmento Ribeiro, A.B. (2021). Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia\u2014From Molecular Mechanisms to Clinical Relevance. Cancers, 13.","DOI":"10.3390\/cancers13194820"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"106458","DOI":"10.1016\/j.leukres.2020.106458","article-title":"The Specificity of Asciminib, a Potential Treatment for Chronic Myeloid Leukemia, as a Myristate-Pocket Binding ABL Inhibitor and Analysis of Its Interactions with Mutant Forms of BCR-ABL1 Kinase","volume":"98","author":"Manley","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/jalm\/jfae096","article-title":"A Novel Next-Generation Sequencing Assay for the Identification of BCR::ABL1 Transcript Type and Accurate and Sensitive Detection of TKI-Resistant Mutations","volume":"9","author":"Yan","year":"2024","journal-title":"J. Appl. Lab. Med."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 Compound Mutations in Tyrosine Kinase Inhibitor\u2013Resistant CML: Frequency and Clonal Relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2019-123409","article-title":"Droplet Digital PCR Phasing (DROP-PHASE): A Novel Method for Straightforward Detection of BCR-ABL1 Compound Mutations in Tyrosine Kinase Inhibitors Resistant Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL)","volume":"134","author":"Vannuffel","year":"2019","journal-title":"Blood"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1182\/blood.V126.23.5167.5167","article-title":"High Frequencies of Compound BCR-ABL Mutations and Their Association with Imatinib Resistant, Disease Progression and Late Chronic Phase Disease in Pakistani Chronic Myeloid Leukemia Patients Necessitate the Inclusion of Molecular Testing in Routine Clinical Settings","volume":"126","author":"Iqbal","year":"2015","journal-title":"Blood"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00432-014-1845-6","article-title":"Next-Generation Deep Sequencing Improves Detection of BCR-ABL1 Kinase Domain Mutations Emerging under Tyrosine Kinase Inhibitor Treatment of Chronic Myeloid Leukemia Patients in Chronic Phase","volume":"141","author":"Kulvait","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.3324\/haematol.2022.281493","article-title":"Measurable Residual Disease in Chronic Myeloid Leukemia","volume":"107","author":"Branford","year":"2022","journal-title":"Haematologica"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"e6849","DOI":"10.1002\/cam4.6849","article-title":"Exploration of Treatment-free Remission in CML, Based on Molecular Monitoring","volume":"13","author":"Zhang","year":"2023","journal-title":"Cancer Med."},{"key":"ref_231","first-page":"207","article-title":"Digital PCR (dPCR) Is Able to Anticipate the Achievement of Stable Deep Molecular Response in Adult Chronic Myeloid Leukemia Patients: Results of the DEMONSTRATE Study","volume":"104","author":"Bernardi","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Abruzzese, E., Bocchia, M., Trawinska, M.M., Raspadori, D., Bondanini, F., Sicuranza, A., Pacelli, P., Re, F., Cavalleri, A., and Farina, M. (2023). Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR). Cancers, 15.","DOI":"10.3390\/cancers15164112"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"106728","DOI":"10.1016\/j.leukres.2021.106728","article-title":"Ultra-Deep Sequencing Mutation Analysis of the BCR\/ABL1 Kinase Domain in Newly Diagnosed Chronic Myeloid Leukemia Patients","volume":"111","author":"Park","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1182\/blood.V116.21.2268.2268","article-title":"Ultra-Deep Next-Generation Sequencing (NGS) Detects BCR-ABL1 Kinase Domain Mutations with High Sensitivity and Allows to Monitor the Composition of Distinct Subclones During Tyrosine Kinase Inhibitor Treatment","volume":"116","author":"Grossmann","year":"2010","journal-title":"Blood"},{"key":"ref_235","first-page":"1587","article-title":"Role of Somatic Mutations in Clonal Evolution of Chronic Myeloid Leukemia from Chronic Phase to Blast Phase","volume":"130","author":"Talati","year":"2017","journal-title":"Blood"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2016-08-693630","article-title":"How I Treat Atypical Chronic Myeloid Leukemia","volume":"129","author":"Gotlib","year":"2017","journal-title":"Blood"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ng.2696","article-title":"Somatic SETBP1 Mutations in Myeloid Malignancies","volume":"45","author":"Makishima","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1590\/1414-431x20154557","article-title":"Evaluation of a Father and Son with Atypical Chronic Myeloid Leukemia with SETBP1 Mutations and a Review of the Literature","volume":"48","author":"Wang","year":"2015","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s12185-017-2241-1","article-title":"Somatic SETBP1 Mutations in Myeloid Neoplasms","volume":"105","author":"Makishima","year":"2017","journal-title":"Int. J. Hematol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.exphem.2016.05.014","article-title":"Pharmacological Activation of Wild-Type P53 in the Therapy of Leukemia","volume":"44","author":"Kojima","year":"2016","journal-title":"Exp. Hematol."},{"key":"ref_242","first-page":"593","article-title":"Genetic Alterations in the P53 Gene in the Blast Crisis of Chronic Myelogenous Leukemia: Analysis by Polymerase Chain Reaction Based Techniques","volume":"7","author":"Neubauer","year":"1993","journal-title":"Leukemia"},{"key":"ref_243","doi-asserted-by":"crossref","unstructured":"Ahmadi, S.E., Rahimian, E., Rahimi, S., Zarandi, B., Bahraini, M., Soleymani, M., Safdari, S.M., Shabannezhad, A., Jaafari, N., and Safa, M. (2024). From Regulation to Deregulation of P53 in Hematologic Malignancies: Implications for Diagnosis, Prognosis and Therapy. Biomark. Res., 12.","DOI":"10.1186\/s40364-024-00676-9"},{"key":"ref_244","doi-asserted-by":"crossref","unstructured":"Sobczy\u0144ska-Konefa\u0142, A., Jasek, M., Karabon, L., and Jasku\u0142a, E. (2024). Insights into Genetic Aberrations and Signalling Pathway Interactions in Chronic Lymphocytic Leukemia: From Pathogenesis to Treatment Strategies. Biomark. Res., 12.","DOI":"10.1186\/s40364-024-00710-w"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/blood-2009-05-224071","article-title":"Detailed Analysis of P53 Pathway Defects in Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL): Dissecting the Contribution of 17p Deletion, TP53 Mutation, P53-P21 Dysfunction, and miR34a in a Prospective Clinical Trial","volume":"114","author":"Zenz","year":"2009","journal-title":"Blood"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"874","DOI":"10.18632\/oncotarget.360","article-title":"Mechanisms of AXL Overexpression and Function in Imatinib-Resistant Chronic Myeloid Leukemia Cells","volume":"2","author":"Dufies","year":"2011","journal-title":"Oncotarget"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41392-024-02121-7","article-title":"AXL Signaling in Cancer: From Molecular Insights to Targeted Therapies","volume":"10","author":"Yadav","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1158\/1078-0432.CCR-16-1930","article-title":"Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor\u2013Sensitive and -Resistant Chronic Myeloid Leukemia","volume":"23","author":"Erdmann","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/10428199709042499","article-title":"Recent Progress On the Role of Axl, A Receptor Tyrosine Kinase, in Malignant Transformation of Myeloid Leukemias","volume":"25","author":"Neubauer","year":"1997","journal-title":"Leuk. Lymphoma"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The Molecular Biology of Chronic Myeloid Leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood.V97.6.1823","article-title":"Cell-Cycle-Dependent Activation of Mitogen-Activated Protein Kinase Kinase (MEK-1\/2) in Myeloid Leukemia Cell Lines and Induction of Growth Inhibition and Apoptosis by Inhibitors of RAS Signaling","volume":"97","author":"Morgan","year":"2001","journal-title":"Blood"},{"key":"ref_252","first-page":"140","article-title":"Effects of mitogen-activated protein kinase(MAPK) in cell signal transduction of chronic myelogenous leukemia cell line K562","volume":"22","author":"Shang","year":"2003","journal-title":"Ai Zheng"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/978-3-642-18156-6_18","article-title":"Effect of Mutationally Activated Ras on the Ras to MAP Kinase Signaling Pathway and Growth Inhibition of Myeloid Leukemia Cells by Inhibitors of the MAP Kinase Cascade","volume":"Volume 40","author":"Hiddemann","year":"2001","journal-title":"Acute Leukemias VIII"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1182\/blood.V73.4.889.889","article-title":"Ras Oncogene Mutations Are Rare Late Stage Events in Chronic Myelogenous Leukemia","volume":"73","author":"LeMaistre","year":"1989","journal-title":"Blood"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.semdp.2023.04.007","article-title":"Advances in Molecular Evaluation of Myeloproliferative Neoplasms","volume":"40","author":"Li","year":"2023","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"7139","DOI":"10.1158\/0008-5472.CAN-07-0778","article-title":"Oncogenic NRAS, KRAS, and HRAS Exhibit Different Leukemogenic Potentials in Mice","volume":"67","author":"Parikh","year":"2007","journal-title":"Cancer Res."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1182\/blood-2008-04-152157","article-title":"High-Throughput Sequencing Screen Reveals Novel, Transforming RAS Mutations in Myeloid Leukemia Patients","volume":"113","author":"Tyner","year":"2009","journal-title":"Blood"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"100635","DOI":"10.1016\/j.ctarc.2022.100635","article-title":"Deep Sequencing Reveals the Spectrum of BCR-ABL1 Mutations upon Front-Line Therapy Resistance in Chronic Myeloid Leukemia: An Eastern-Indian Cohort Study","volume":"33","author":"Dey","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2018-04-848028","article-title":"Next-Generation Sequencing\u2013Based Posttransplant Monitoring of Acute Myeloid Leukemia Identifies Patients at High Risk of Relapse","volume":"132","author":"Kim","year":"2018","journal-title":"Blood"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s12094-017-1722-2","article-title":"Targeted Next-Generation Sequencing Identifies Clinically Relevant Mutations in Patients with Chronic Neutrophilic Leukemia at Diagnosis and Blast Crisis","volume":"20","author":"Langabeer","year":"2018","journal-title":"Clin. Transl. Oncol."},{"key":"ref_261","first-page":"2","article-title":"Standardization and Quality Management in Next-Generation Sequencing","volume":"10","author":"Endrullat","year":"2016","journal-title":"Appl. Transl. Genom."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13046-020-01554-6","article-title":"Variants of Uncertain Significance in the Era of High-Throughput Genome Sequencing: A Lesson from Breast and Ovary Cancers","volume":"39","author":"Federici","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"D835","DOI":"10.1093\/nar\/gkz972","article-title":"ClinVar: Improvements to Accessing Data","volume":"48","author":"Landrum","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1146\/annurev-med-102115-021556","article-title":"Next-Generation Sequencing and Result Interpretation in Clinical Oncology: Challenges of Personalized Cancer Therapy","volume":"68","author":"Khotskaya","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1097\/01.HS9.0000850052.30084.5a","article-title":"PB1800: DEEPDECON: A DEEP-LEARNING METHOD FOR DETECTING MINIMAL RESIDUAL DISEASE OF ACUTE MYELOID LEUKEMIA","volume":"6","author":"Zhong","year":"2022","journal-title":"Hemasphere"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41525-018-0067-2","article-title":"FDA Guidance for next Generation Sequencing-Based Testing: Balancing Regulation and Innovation in Precision Medicine","volume":"3","author":"Luh","year":"2018","journal-title":"NPJ Genom. Med."},{"key":"ref_267","unstructured":"(2025, March 23). FDA Approves NGS-Based Test for Patients With ALL or MM|ASH Clinical News|American Society of Hematology. Available online: https:\/\/multiplemyeloma.org.nz\/trial-represents-bold-move-for-treatment-of-newly-diagnosed-myeloma-2-2-2-2\/."},{"key":"ref_268","first-page":"259","article-title":"The Limits of FDA\u2019s Authority to Regulate Clinical Research Involving High-Throughput DNA Sequencing","volume":"70","author":"Evans","year":"2015","journal-title":"Food Drug Law J."},{"key":"ref_269","unstructured":"(2025, March 23). CMS Finalizes Coverage of Next Generation Sequencing Tests, Ensuring Enhanced Access for Cancer Patients|CMS, Available online: https:\/\/www.cms.gov\/newsroom\/press-releases\/cms-finalizes-coverage-next-generation-sequencing-tests-ensuring-enhanced-access-cancer-patients."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"100376","DOI":"10.1016\/j.jcpo.2022.100376","article-title":"Cancer Patient Management: Current Use of next-Generation Sequencing in the EU TOP4","volume":"35","author":"Hedblom","year":"2023","journal-title":"J Cancer Policy"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and Management of AML in Adults: 2022 Recommendations from an International Expert Panel on Behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/ejh.12603","article-title":"Leukemia Diagnosis: Today and Tomorrow","volume":"95","author":"Grimwade","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jmoldx.2017.01.011","article-title":"Guidelines for Validation of Next-Generation Sequencing\u2013Based Oncology Panels","volume":"19","author":"Jennings","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"ref_274","doi-asserted-by":"crossref","unstructured":"Horgan, D., Curigliano, G., Rie\u00df, O., Hofman, P., B\u00fcttner, R., Conte, P., Cufer, T., Gallagher, W.M., Georges, N., and Kerr, K. (2022). Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe. JPM, 12.","DOI":"10.3390\/jpm12010072"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"e18754","DOI":"10.1200\/JCO.2021.39.15_suppl.e18754","article-title":"Barriers to Next-Generation Sequencing despite Increased Utilization: U.S. Physician Survey Results","volume":"39","author":"Kaminski","year":"2021","journal-title":"JCO"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1182\/blood-2024-208059","article-title":"Impact of Ultra Rapid Molecular Profiling on Treatment Delays and Healthcare Utilization of Patients Hospitalized for Acute Leukemia","volume":"144","author":"Dhawale","year":"2024","journal-title":"Blood"},{"key":"ref_277","first-page":"723","article-title":"The Role of Next-Generation Sequencing in Acute Myeloid Leukemia","volume":"34","author":"Llop","year":"2022","journal-title":"Curr. Opin. Oncol."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/leu.2017.308","article-title":"The Role of Bone Marrow Morphology in the Diagnosis of Relapsed Acute Myeloid Leukemia","volume":"32","author":"Said","year":"2018","journal-title":"Leukemia"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"e18757","DOI":"10.1200\/JCO.2021.39.15_suppl.e18757","article-title":"Survey Study of Barriers to Evidence-Based Decision-Making in Oncology Care Using next-Generation Sequencing","volume":"39","author":"Szamreta","year":"2021","journal-title":"JCO"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.ccell.2022.08.011","article-title":"Clinical Application of Advanced Multi-Omics Tumor Profiling: Shaping Precision Oncology of the Future","volume":"40","author":"Akhoundova","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_282","doi-asserted-by":"crossref","unstructured":"Ha, K.C., Lalonde, E., Li, L., Cavallone, L., Natrajan, R., Lambros, M.B., Mitsopoulos, C., Hakas, J., Kozarewa, I., and Fenwick, K. (2011). Identification of Gene Fusion Transcripts by Transcriptome Sequencing in BRCA1-Mutated Breast Cancers and Cell Lines. BMC Med. Genom., 4.","DOI":"10.1186\/1755-8794-4-75"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.semcancer.2021.09.013","article-title":"Transcriptomics Paving the Way for Improved Diagnostics and Precision Medicine of Acute Leukemia","volume":"84","author":"Mitelman","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"100007","DOI":"10.1016\/j.clnves.2025.100007","article-title":"Multi-Omics Advances for Molecular Characterization, Precision Medicine, and Prognostic Implications in Leukemia","volume":"1","author":"Hou","year":"2025","journal-title":"Cell Investig."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"100517","DOI":"10.1016\/j.mcpro.2023.100517","article-title":"Proteomic Characterization of Acute Myeloid Leukemia for Precision Medicine","volume":"22","author":"Casado","year":"2023","journal-title":"Mol. Cell. Proteom."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41375-018-0032-1","article-title":"Proteomic and Genomic Integration Identifies Kinase and Differentiation Determinants of Kinase Inhibitor Sensitivity in Leukemia Cells","volume":"32","author":"Casado","year":"2018","journal-title":"Leukemia"},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1016\/j.apsb.2024.07.004","article-title":"Spatial Metabolomics Highlights Metabolic Reprogramming in Acute Myeloid Leukemia Mice through Creatine Pathway","volume":"14","author":"Bao","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cancergen.2024.12.006","article-title":"Omics Approaches: Role in Acute Myeloid Leukemia Biomarker Discovery and Therapy","volume":"292\u2013293","author":"Shafiei","year":"2025","journal-title":"Cancer Genet."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41420-024-01803-z","article-title":"Cancer Epigenetics: From Laboratory Studies and Clinical Trials to Precision Medicine","volume":"10","author":"Yu","year":"2024","journal-title":"Cell Death Discov."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/leu.2011.342","article-title":"DNMT3A Mutations and Response to the Hypomethylating Agent Decitabine in Acute Myeloid Leukemia","volume":"26","author":"Metzeler","year":"2012","journal-title":"Leukemia"},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13148-024-01771-2","article-title":"TET2 Mutation in Acute Myeloid Leukemia: Biology, Clinical Significance, and Therapeutic Insights","volume":"16","author":"Gao","year":"2024","journal-title":"Clin. Epigenet."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"e36155","DOI":"10.1016\/j.heliyon.2024.e36155","article-title":"Molecular Precision Medicine: Multi-Omics-Based Stratification Model for Acute Myeloid Leukemia","volume":"10","author":"Wang","year":"2024","journal-title":"Heliyon"},{"key":"ref_293","doi-asserted-by":"crossref","unstructured":"Kosvyra, A., Karadimitris, A., Papaioannou, \u039c., and Chouvarda, I. (2024). Machine Learning and Integrative Multi-Omics Network Analysis for Survival Prediction in Acute Myeloid Leukemia. Comput. Biol. Med., 178.","DOI":"10.1016\/j.compbiomed.2024.108735"},{"key":"ref_294","doi-asserted-by":"crossref","unstructured":"Mohr, A.E., Ortega-Santos, C.P., Whisner, C.M., Klein-Seetharaman, J., and Jasbi, P. (2024). Navigating Challenges and Opportunities in Multi-Omics Integration for Personalized Healthcare. Biomedicines, 12.","DOI":"10.3390\/biomedicines12071496"},{"key":"ref_295","doi-asserted-by":"crossref","unstructured":"Tsagiopoulou, M., and Gut, I.G. (2024). Machine Learning and Multi-Omics Data in Chronic Lymphocytic Leukemia: The Future of Precision Medicine?. Front. Genet., 14.","DOI":"10.3389\/fgene.2023.1304661"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"e25369","DOI":"10.1016\/j.heliyon.2024.e25369","article-title":"A Machine Learning and Deep Learning-Based Integrated Multi-Omics Technique for Leukemia Prediction","volume":"10","author":"Abbasi","year":"2024","journal-title":"Heliyon"},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/s41587-021-01108-x","article-title":"Nanopore Sequencing Technology, Bioinformatics and Applications","volume":"39","author":"Wang","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hon.2739","article-title":"Clinical Potential of Introducing Next-Generation Sequencing in Patients at Relapse of Acute Myeloid Leukemia","volume":"38","author":"Flach","year":"2020","journal-title":"Hematol. Oncol."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2023-179536","article-title":"Impact of Real-World Treatment Sequencing Patterns on Time to Next Treatment among Patients with Chronic Lymphocytic Leukemia in the United States","volume":"142","author":"Challagulla","year":"2023","journal-title":"Blood"},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/ijlh.13711","article-title":"Comparison of Flow Cytometry and Next-Generation Sequencing in Minimal Residual Disease Monitoring of Acute Myeloid Leukemia: One Institute\u2019s Practical Clinical Experience","volume":"44","author":"McGowan","year":"2022","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jgg.2024.09.007","article-title":"Nanopore Sequencing: Flourishing in Its Teenage Years","volume":"51","author":"Zhang","year":"2024","journal-title":"J. Genet. Genom."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jmoldx.2022.05.003","article-title":"Comprehensive Validation of Diagnostic Next-Generation Sequencing Panels for Acute Myeloid Leukemia Patients","volume":"24","author":"Wagner","year":"2022","journal-title":"J. Mol. Diagn."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.drudis.2018.05.015","article-title":"Next-Generation Sequencing in Drug Development: Target Identification and Genetically Stratified Clinical Trials","volume":"23","author":"Wang","year":"2018","journal-title":"Drug Discov. Today"},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/01.JAA.0000550287.71026.23","article-title":"Clinical Utility of Next-Generation Sequencing in Precision Oncology","volume":"32","author":"Hux","year":"2019","journal-title":"JAAPA"},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-024-01760-0","article-title":"New Clinical Trial Design in Precision Medicine: Discovery, Development and Direction","volume":"9","author":"Duan","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1182\/hematology.2023000429","article-title":"The Future Paradigm of HMA + VEN or Targeted Inhibitor Approaches: Sequencing or Triplet Combinations in AML Therapy","volume":"2023","author":"Venugopal","year":"2023","journal-title":"Hematology"},{"key":"ref_307","doi-asserted-by":"crossref","unstructured":"Dhawan, D. (2017). Clinical Next-Generation Sequencing. Progress and Challenges in Precision Medicine, Elsevier.","DOI":"10.1016\/B978-0-12-809411-2.00002-7"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/17\/2\/18\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:04:35Z","timestamp":1760029475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/17\/2\/18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":307,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["hematolrep17020018"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep17020018","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]}}}